Product Reports Resources Pricing Login Book a demo

Viridian Therapeutics

Biotech & Life Sciences · Boulder, United States · Founded 2007 · IPO 2017

Viridian Therapeutics is a biopharmaceutical company that discovers and develops microRNA (miRNA)-targeting therapies. The company is focused on developing innovative therapies for thyroid eye disease through advanced monoclonal antibody technology targeting the IGF-1R pathway. Viridian Therapeutics operates in the biopharmaceutical market, specifically focusing on rare autoimmune diseases. Its clients are patients suffering from these conditions. The company's business model revolves around the discovery, development, and subsequent commercialization of novel treatments. As a clinical-stage biopharmaceutical company, its revenue generation will likely depend on the successful approval and market launch of its therapeutic candidates. Keywords: biopharmaceutical, microRNA, antibody engineering, autoimmune diseases, thyroid eye disease, monoclonal antibody, IGF-1R, rare diseases, clinical-stage, drug development

Valuation $1.44B
Revenue $71M
Total funding $100–500M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue
Featured in
News Viridian Therapeutics raises $350M in upsized dual public offerings Jun 3, 2026

Investors

13 investors on Viridian Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Boulder Ventures
Atlas Venture
Broadview Ventures
Amgen Ventures
Remeditex Ventures
Series B+ 8 investors entered at this stage
MP Healthcare Venture Management
JAFCO
Brace Pharma
MRL Ventures
Fidelity Investments
Hercules Capital
Braidwell
DRI Healthcare

Global footprint

Where Viridian Therapeutics has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States98.2%
🇫🇷 France0.3%
🇦🇹 Austria0.3%
🇰🇼 Kuwait0.3%
🇬🇧 United Kingdom0.3%
Top 5 of 6 shown
Web traffic by country
17K monthly visits
across markets
🇺🇸 United States47.6%
🇨🇦 Canada25.3%
🇮🇳 India10.6%
🇬🇧 United Kingdom5.9%
🇵🇭 Philippines2.9%
Top 5 markets shown

Talent graph

The shape of Viridian Therapeutics's talent

Dealroom maps Viridian Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

18 standout operatorsDealroom-flagged across the org
1 AI specialistpinpointed by name
278 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Viridian Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$59M patent portfolio · 32 active families

Estimated portfolio value
$59M
4.1% of market cap · 1.6× smaller than top peer WuXi Biologics ($95M)
32 active patent families
Where Viridian Therapeutics innovates Antiendomysial antibodiesBiologyDiseaseEye diseaseMedicinal chemistry

Where Viridian Therapeutics concentrates vs peers

Each axis is a top-10 topic across Viridian Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Viridian Therapeutics

An AI-synthesized read of the highest-engagement posts about Viridian Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Viridian Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles